JPMorgan Chase & Co. Boosts Grifols (NASDAQ:GRFS) Price Target to $10.30

Grifols (NASDAQ:GRFS - Get Free Report) had its price objective upped by JPMorgan Chase & Co. from $7.60 to $10.30 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 17.45% from the stock's previous close.

Separately, Wall Street Zen upgraded Grifols from a "hold" rating to a "buy" rating in a research note on Friday, May 23rd.

Grifols Price Performance

GRFS stock traded up $0.07 during midday trading on Tuesday, reaching $8.77. 1,275,233 shares of the company's stock traded hands, compared to its average volume of 1,155,871. The company has a 50-day simple moving average of $7.86 and a two-hundred day simple moving average of $7.59. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. Grifols has a 1-year low of $5.79 and a 1-year high of $9.96. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 7.50, a PEG ratio of 0.31 and a beta of 0.53.

Institutional Trading of Grifols

Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. raised its position in Grifols by 344.4% in the 4th quarter. Blue Trust Inc. now owns 8,697 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 6,740 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Grifols by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after buying an additional 1,657 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Grifols during the fourth quarter worth $91,000. Highland Peak Capital LLC raised its position in shares of Grifols by 29.5% during the fourth quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock worth $5,849,000 after acquiring an additional 179,114 shares during the last quarter. Finally, HighTower Advisors LLC lifted its stake in shares of Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after acquiring an additional 3,936 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.